GlassScriptPhysician profile
Steven Seth Cohen
NPI 1255353785
$126,634.62
in general payments reported to CMS, 2019-2025
64 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $6,149 · 2021: $2,656 · 2022: $37K · 2023: $42K · 2024: $11K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Travel and Lodging: $15K · Food and Beverage: $13K · Consulting Fee: $6,160 · Honoraria: $58.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,848.50 |
| Travel and Lodging | $15,029.47 |
| Food and Beverage | $13,298.19 |
| Consulting Fee | $6,160.00 |
| Honoraria | $58.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67,240.87 | 2022-2025 | Verquvo, Capvaxive, Belsomra |
| Boston Scientific Corporation | $18,862.98 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $12,904.52 | 2021-2025 | |
| Abbott Laboratories | $6,683.98 | 2019-2025 | Aveir, Mitraclip, Amplatzer Amulet |
| Pfizer INC. | $4,059.72 | 2019-2025 | |
| Atricure, INC. | $2,412.32 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,834.36 | 2019-2025 | Wainua, Lokelma, Airsupra |
| Medtronic, INC. | $1,170.87 | 2021-2024 | Corevalve Evolut R, Micra, Intellis Adaptivestim |
| Novo Nordisk INC | $1,082.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,079.59 | 2019-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,002.45 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $755.98 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $690.37 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $498.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $493.73 | 2019-2023 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.